Healthcare entity
All 3 tracked stories fall under one category: regulation. Of the tracked stories, 2 of 3 also mention Donald Trump, the most common co-covered peer. That works out to roughly 0.3 stories per week across a 63-day span. The busiest single day carried 2.
Last mentioned: 2d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: regulation. Of the tracked stories, 2 of 3 also mention Donald Trump, the most common co-covered peer. That works out to roughly 0.3 stories per week across a 63-day span. The busiest single day carried 2. Source depth averages 8 original sources per story, versus 3.2 across the same-window beat baseline. The 6.3 average consequence score is above the beat benchmark of 5.9 in the same window. This profile follows 3 Healthcare stories mentioning Karim Mikhail across the period from July 9, 2026 to September 9, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 490 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Karim Mikhail. Shared-story counts are live from our verified record — not editorial picks.
HHS announces permanent FDA center directors
Four senior positions filled, including permanent directors for drugs, vaccines/biologics, and tobacco products.
HHS fills four senior FDA roles
The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
Tracy Beth Høeg departs CDER
Høeg says she was fired as director of the FDA's Center for Drug Evaluation and Research.
Michael Davis assumes acting CDER director
Davis steps in as acting director of CDER following Høeg's departure.
Michael Davis returns to FDA as deputy director
Davis rejoins the agency after working at a nonprofit pursuing psychedelic drug development.
FDA gains stability as HHS fills four senior roles, with permanent directors for drug, vaccine and tobacco centers. The moves follow months of upheaval and could reshape regulatory timelines, safety oversight, and public health policy.
HHS has made permanent four acting officials at the FDA's drug, vaccine, and tobacco centers, reducing leadership uncertainty for health systems, clinicians, and patients. The moves follow months of controversy and high-profile departures.
The FDA’s approval of Casgevy for children as young as two promises to shift pediatric sickle cell care from lifelong management to a one-time curative intervention, but raises urgent questions about cost, access, and health equity.
Karim Mikhail is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
